Suzetrigine

Suzetrigine
Clinical data
Pronunciation	/suˈzɛtrɪdʒiːn/; soo-ZE-tri-jeen
Trade names	Journavx
Other names	VX-548
AHFS/Drugs.com	Monograph
MedlinePlus	a625039
License data	US DailyMed: Suzetrigine;
Routes of; administration	By mouth
Drug class	Nav1.8 sodium channel blocker; analgesic
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 4-[[(2R,3S,4S,5R)-3-(3,4-Difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide;
CAS Number	2649467-58-1;
PubChem CID	156445116;
DrugBank	DB18927;
ChemSpider	128942439;
UNII	LOG73M21H5;
KEGG	D12860;
ChEMBL	ChEMBL5314487;
Chemical and physical data
Formula	C21H20F5N3O4
Molar mass	473.400 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1c([C@H]2[C@H](C(=O)Nc3ccnc(C(N)=O)c3)O[C@@](C)(C(F)(F)F)[C@H]2C)ccc(F)c1F;
	InChI InChI=1S/C21H20F5N3O4/c1-9-14(11-4-5-12(22)15(23)16(11)32-3)17(33-20(9,2)21(24,25)26)19(31)29-10-6-7-28-13(8-10)18(27)30/h4-9,14,17H,1-3H3,(H2,27,30)(H,28,29,31)/t9-,14-,17-,20-/m0/s1; Key:XSQUJFKRXZMOKA-PAFIKIDNSA-N;

Suzetrigine, sold under the brand name Journavx, is an oral medication used for moderate to severe acute pain management in adults. It is a small-molecule non-opioid analgesic that works as a selective inhibitor of Na_v1.8-dependent pain-signaling pathways in the peripheral nervous system. Na_v1.8 channels are predominantly present in peripheral nociceptive neurons of the dorsal root ganglia. Suzetrigine inhibits pain signals before they reach the central nervous system and has no addictive potential.

The most common adverse reactions include itching, muscle spasms, increased blood level of creatine phosphokinase, and rash.

Suzetrigine was developed by Vertex Pharmaceuticals. It was approved for medical use in the United States on January 30, 2025. Suzetrigine is a first-in-class non-opioid analgesic approved by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe acute pain.